IRLAB Therapeutics AB

Den positiva utvecklingen håller i sig! Detta är den sista kvartalsrapporten som jag kommenterar i min roll som vd och jag skulle därför vilja passa på att tacka alla aktieägare för det förtroende som ni givit mig under min tid som vd för företaget. Jag vill även tacka alla medarbetare för det fantastiska arbete som utförts och lett till det gångna årets alla framgångar i projektportföljen. Jag ser fram emot att få fortsätta arbeta i bolagets styrelse och vara delaktig i utveckling och kapitalisering av alla våra banbrytande läkemedelsprojekt. Den positiva utvecklingen i början av året håller i sig och även det andra kvartalet har varit mycket händelserikt med flera viktiga framsteg. ✅ Vi har inlett vår fas I-studie med IRL757, ingått ett samarbete med MSRD/Otsuka gällande den fortsatta kliniska utvecklingen genom kliniskt Proof-of-Concept, erhållit DSMB:s enhälliga rekommendation att fortsätta React-PD-studien med pirepemat enligt plan samt rekryterat en ny vd till bolaget. ✅ Våra förberedelser för att kunna starta Fas III-programmet med mesdopetam för behandling av levodopainducerade dyskinesier fortgår. Under det gångna kvartalet har vi haft ett stort fokus på partnerdiskussioner, förberedelser av interaktioner med europeiska myndigheter inför start av Fas III, samt marknadsundersökningar som led i positioneringen inför en framtida lansering av produkten. ✅ Den 1 augusti välkomnar vi IRLAB:s nya vd Kristina Torfgård. Jag ser fram emot att få samarbeta och stötta henne från min position som styrelsemedlem i IRLAB. Efter ett mycket framgångsrikt första halvår fortsätter vi resan framåt med orubbligt fokus på våra innovativa portföljprojekt som alla har potential att bli first-in-class läkemedel och revolutionera behandlingen av Parkinsons sjukdom. Gunnar Olsson, vd

📢 IRLAB publishes interim report for the period January-June 2024 KEY HIGHLIGHTS DURING AND AFTER THE PERIOD: ⚫ Collaboration with MSRD/Otsuka, funding IRL757 through clinical Proof-of-Concept. ⚫ Successful End-of-Phase 2-meeting with FDA for mesdopetam. ⚫ New insights from the Phase IIb study with pirepemat. ⚫ Regulatory approval to start Phase I with IRL757. ⚫ Kristina Torfgård appointed CEO, starting August 1, 2024. ⚫ Pirepemat passed the independent Data Safety Monitoring Board (DSMB) conducted the last of two predetermined reviews of safety and data integrity in the Phase IIb study, React-PD. The DSMB unanimously recommended that the study should continue without any changes. 👉 Read the full report on our website: https://lnkd.in/dfhtMuJV

📢 Invitation to the interim report for Q2 2024 presentation and webcast IRLAB Therapeutics will hold a presentation in conjunction with the publication of the interim report for the period January-June 2024. The interim report will be published on Wednesday, July 10 at 07:00 CEST. The presentation will be held on July 10, 2024, at 10:00 CEST via digital webcast. Gunnar Olsson, CEO, Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will comment the interim report. The presentation will be held in English and will be followed by a Q&A session. 👉 Follow the webcast online: https://lnkd.in/dSZNctJG

📢 Press Release: IRLAB’s Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee IRLAB is pleased to announce that the independent Data Safety Monitoring Board (DSMB) has completed the last of two pre-determined safety and data integrity reviews of the ongoing Phase IIb study of pirepemat. The DSMB unanimously recommends that the study should continue without any changes. In accordance with the previously communicated plan, IRLAB will complete patient recruitment in the third quarter of 2024. "Following the positive opinion from the independent safety committee, DSMB, we can now complete the study in full accordance with the study protocol. Our aim is to always maintain the highest possible patient safety and a rigorous scientific approach, where DSMB reviews are an important part," says Gunnar Olsson, CEO of IRLAB. 👉 Read the full press release on our website: https://lnkd.in/dgUFnSE5 #parkinsonsdisease

Are you an ADME specialist and DMPK project team lead? We seek a highly skilled and experienced individual to join our development team in a senior role. This is a unique opportunity to contribute to advancing novel treatments for Parkinson's disease. IRLAB Therapeutics is a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease. We are in modern lab facilities in Gothenburg on the West Coast of Sweden. For more information and application, follow this link: https://lnkd.in/dXcjd4jG #hiring #adme #dmpk #drugdevelopment #drugdiscovery

Are you an ADME specialist and DMPK project team lead? We seek a highly skilled and experienced individual to join our development team in a senior role. This is a unique opportunity to contribute to advancing novel treatments for Parkinson's disease. IRLAB Therapeutics is a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease. We are in modern lab facilities in Gothenburg on the West Coast of Sweden. For more information and application, follow this link: https://lnkd.in/dXcjd4jG #hiring #adme #dmpk #drugdevelopment #drugdiscovery

Did you know that apathy is a common condition in neurodegenerative diseases? Apathy can best be described as no or very low feelings of motivation. It is usually characterized as a lack of emotion or interest in yourself and the world around you. The condition can significantly diminish one's interest in social interactions and activities they once found joy in. Often, it's the family members who first notice these changes and seek help. Apathy is a debilitating condition affecting over 10 million people in the US and equally many in Europe. The prevalence is high, occurring in 20–70 percent of people with Parkinson’s and 20–90 percent of people with disorders such as Alzheimer’s disease and other disorders related to CNS. At present, there are no specific treatments for apathy. The most common therapies are antidepressants, psychotherapy, and complementary therapies like yoga and tai chi. Our drug candidate, IRL757, aims to treat apathy in neurological disorders by reverse disruption in cortical to sub-cortical nerve signaling, a proposed mechanism underlying apathy in neurological disorders. With the support of The Michael J. Fox Foundation for Parkinson's Research, we recently initiated the first Phase I clinical trial of IRL757 to document the safety, tolerability, and pharmacokinetic properties of the drug candidate in healthy subjects. The study is expected to be completed in 2024. Follow us to learn more! #apathy #parkinsonsdisease #alzheimers #irlabtherapeutics #drugdiscovery        

Could mesdopetam have a disease-modifying effect?   In a recent study published in the esteemed scientific journal Frontiers in Aging Neuroscience, Chinese scientists investigated the effects of mesdopetam on the synaptic structure of dopamine-expressing neurons in a preclinical model for levodopa-induced dyskinesia (LID).   What they found was quite exceptional – treatment with mesdopetam not only improved the dyskinesia but also restored the alterations in reduced dendritic spine density in the synaptic regions of dopaminergic neurons.   “These results indicate that in addition to having an effect on dyskinesia, mesdopetam could also have a potential disease-modifying effect with the ability to restore the synaptic structure and functional plasticity of the neurons affected by long-term treatment with levodopa. This means that treatment with mesdopetam does not only reduce dyskinesia in the short-term, but may also reduce the propensity of levodopa treatment to induce dyskinesia,” says Dr Joakim Tedroff, Chief Medical Officer, IRLAB.   ➡ Read the whole story in the original article attached as a PDF. Wang X and Zhang W (2024) IRL790 modulated striatal D1 neurons synaptic plasticity ameliorating levodopa-induced dyskinesia in mouse. Front. Aging Neurosci. 16:1401991.   Follow us for more insights on our work discovering and developing novel treatments for #parkinsonsdisease #irlabtherapeutics #CNS #drugdiscovery #drugdevelopment #dyskinesia  

Idag medverkade vår VD Gunnar Olsson på Aktiespararnas event Stora Aktiedagarna för att presentera IRLAB och svara på frågor om bolagets senaste framsteg och vad som väntar runt hörnet.   Följ oss för att få veta mer om vårt arbete med att upptäcka och utveckla nya behandlingar mot #parkinsonsdisease #irlabtherapeutics #CNS #drugdiscovery #drugdevelopment

IRLAB will give a presentation at Stora Aktiedagarna taking place in Stockholm, June 11-12. Gunnar Olsson, CEO, will give a 25-minute company presentation, including a Q&A session on June 12 at 13.30 CEST. The event is held at Birger Jarl Conference, Birger Jarlsgatan 61 A in Stockholm. Don't miss this chance to learn more about our work discovering and developing novel treatments for Parkinson’s disease. More information can be found on Aktiespararna’s webpage: https://lnkd.in/dtuewa_x #parkinsonsdisease